TREMFYA (guselkumab) is the first medication of its kind to be approved by the Food and Drug Administration (FDA) in 2017 to treat adults with moderate to severe plaque psoriasis. In July 2020, the FDA also approved TREMFYA to treat adults with active psoriatic arthritis.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

TREMFYA REFERRAL FORM

What it treats

Plaque Psoriasis & Psoriatic Arthritis

Prescribed by

Dermatologists & Rheumatologists

How it’s administered

Intravenous (IV) infusion
or subcutaneous injection

Frequency

Single 100mg injection (Day 1), 1 injection
4 weeks later & 1 injection every 8 weeks

Length of treatment

8 weeks